The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

AFL great, turned Cerutty Macro Fund portfolio manager, Chris Judd is with HP Rx founder and managing partner Hashan De Silva for today’s Talk Ya Book.

They discuss CurveBeam AI (ASX:CVB), a company in which Mr De Silva is a director. Mr De Silva holds 565,493 ordinary shares, millions of options and 320,928 indirect shares.

The company’s developed a CT scanning device, called HiRise, that works when a patient is weight-bearing, providing imaging while patients are standing. The images can be done within an orthopaedic centre, and release lower radiation levels.

CurveBeam has a market cap of $36 million and was trading at 16 cents (May 28).

KP Rx invests in a diverse range of biotech, medical device, diagnostic, and health tech companies located predominantly in Australia and New Zealand. It is backed by Karst Peak Capital.

Talk Ya Book was created by Chris Judd in 2019 as a show where fund managers could share their highest conviction investment idea but more importantly showcase their investment framework to the public.

Disclaimer: Juddcorp Pty Ltd ACN 635 629 631 is a corporate authorised representative (CAR) (CAR Number 1300536) of Boutique Capital Pty Ltd ACN 621 697 621 AFSL 508011.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

More From The Market Online
3D image of ovarian cancer

Cleo Diagnostics patents ovarian cancer test IP; shares jump on low liquidity

Ovarian cancer detection biotech Cleo Diagnostics (ASX: COV) has seen shares jump towards +4% on Wednesday as it patents
Exit sign

Paradigm Biopharma draws ire as administrators called in one week after suspension

Paradigm Biopharma (ASX:PAR) has made the sad move of calling in voluntary administrators on Wednesday after the latest data
Nasal spray

Firebrick Pharma flags intention to enter US market with nasal iodine product

Firebrick Pharma (ASX:FRE) has formally earmarked its ambitions to penetrate the US retail market with its Nasodine (nasal iodine)
The Market Online Video

Wealth Within: 3 ASX Stocks to Watch for October’s Market Rebound

Could October finally deliver the ASX rebound investors have been waiting for? After a difficult September, Wealth Within’s Filip Tortevski and Pedro Banales